One important problem that may arise during PARP inhibitor treatment is the development of resistance. Even BRCA-deficient mouse tumors were reported to acquire resistance to PARP inhibitors.

PARP inhibitor treatment can induce various resistance mechanisms, including re-activating BRCA mutations, mutations in HR-inhibiting genes and upregulation of drug efflux pumps. Clinical ...

The Institute of Cancer Research, London, is seeking a partner to collaborate on the development of anti-cancer vaccines and/or immunotherapeutic approaches to help overcome resistance to PARP ...

Pancreatic cancer is a highly lethal digestive malignancy with a 5-year survival rate of 10%. So far, the available therapeutic strategies are scarce and the few advancements made, as is the case of ...

AstraZeneca and Merck & Co's Lynparza has been the undisputed market leader in the PARP inhibitor category for ... naïve metastatic castration-resistant prostate cancer (mCRPC) whose disease ...

Results from the PAOLA-1 study showed that the PARP inhibitor drug significantly ... in metastatic castration-resistant prostate cancer (mCRPC). In other AstraZeneca news, the company’s ...